GlassScriptPhysician profile
Jun K Chung
NPI 1295758191
$4,743.00
in general payments reported to CMS, 2019-2025
28 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $709 · 2020: $697 · 2021: $687 · 2022: $1,004 · 2023: $1,159 · 2024: $327 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,646.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $504.01 | 2020-2023 | |
| Abbott Laboratories | $489.96 | 2019-2025 | Xience Skypoint, Xience Sierra |
| Teleflex LLC | $462.67 | 2019-2024 | Supercross, Manta, Spectre |
| Astrazeneca Pharmaceuticals LP | $450.52 | 2019-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $416.32 | 2019-2023 | Xarelto |
| Medtronic, INC. | $412.84 | 2021-2025 | Tyrx, Selectsecure, Linq II |
| Amgen INC. | $353.82 | 2019-2023 | Repatha |
| Boston Scientific Corporation | $250.29 | 2019-2024 | Jetstream Sc, Ekosonic, Lux-Dx Insertable Cardiac Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $208.40 | 2019-2024 | Lifevest |
| Medtronic Vascular, INC. | $177.07 | 2019-2020 | |
| Novo Nordisk INC | $146.65 | 2023-2025 | Ozempic, Rybelsus, Tresiba |
| Pfizer INC. | $144.96 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.64 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $85.46 | 2023-2024 | Eliquis, Opdivo |
| Philips North America LLC | $81.55 | 2019-2024 | (Ck6) Holter |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $58.17 | 2019-2022 | |
| Astellas Pharma US INC | $57.41 | 2019-2021 | |
| Cardiovascular Systems INC. | $52.66 | 2020-2022 | |
| Daiichi Sankyo INC. | $50.17 | 2022-2023 | Injectafer |
| Terumo Medical Corporation | $41.49 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $34.11 | 2022 | |
| Edwards Lifesciences Corporation | $29.16 | 2021 | |
| Abiomed | $27.16 | 2019 | |
| Vital Connect, INC | $25.62 | 2024 | Vitalpatch Rtm |
| W. L. Gore & Associates, INC. | $24.93 | 2019-2022 | |
| Cardiva Medical, INC. | $23.06 | 2022 | |
| Alnylam Pharmaceuticals INC. | $16.75 | 2023 | Onpattro |
| Cardinal Health 200 LLC | $14.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.